ReviewOxidative medicine and cellular longevity2012
The bad, the good, and the ugly about oxidative stress.
Review in Oxidative medicine and cellular longevity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Dexmedetomidine Exerts Multi-level Effects to Ameliorate Alzheimer's Disease Pathology in the Adult Zebrafish Brain.Molecular neurobiology · 2026Article
- Effect ofFrontiers in veterinary science · 2024Article
- Limited expression of Nrf2 in neurons across the central nervous system.Redox biology · 2023Article
- An antioxidant response element regulates the HIF1α axis in breast cancer cells.Free radical biology & medicine · 2023Article
- Limited Expression ofbioRxiv : the preprint server for biology · 2023Article
- Shifting gears: Study of immune system parameters of male habitual marathon runners.Frontiers in immunology · 2022Article
- Mitochondria: Insights into Crucial Features to Overcome Cancer Chemoresistance.International journal of molecular sciences · 2021Review
- Vitamin E TPGS 1000 Induces Apoptosis in the K562 Cell Line: Implications for Chronic Myeloid Leukemia.Oxidative medicine and cellular longevity · 2021Article
- Primaquine-quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species.Malaria journal · 2019Article
- Modulation by hydroxytyrosol of oxidative stress and antitumor activities of paclitaxel in breast cancer.European journal of nutrition · 2019Article
- A distinct class of antioxidant response elements is consistently activated in tumors with NRF2 mutations.Redox biology · 2018Article
- Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling.International journal of molecular sciences · 2017Review
- Oxidative Stress Evaluation in Patients Treated with Orthodontic Self-ligating Multibracket Appliances: AnThe open dentistry journal · 2017Article
- The Roles of ROS in Cancer Heterogeneity and Therapy.Oxidative medicine and cellular longevity · 2017Review
- Gene regulatory effects of disease-associated variation in the NRF2 network.Current opinion in toxicology · 2016Article
- Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.Neurochemical research · 2016Article
- Direct and protective effects of single or combined addition of vincristine and ε-viniferin on human HepG2 cellular oxidative stress markers in vitro.Cytotechnology · 2016Article
- 1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative Stress.Oxidative medicine and cellular longevity · 2016Review
- Article
- Beyond antioxidant genes in the ancient Nrf2 regulatory network.Free radical biology & medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), Parkinson's disease (PD), and cancer (e.g., leukemia) are the most devastating disorders affecting millions of people worldwide. Except for some kind of cancers, no effective and/or definitive therapeutic treatment aimed to reduce or to retard the clinic and pathologic symptoms induced by AD and PD is presently available. Therefore, it is urgently needed to understand the molecular basis of these disorders. Since oxidative stress (OS) is an important etiologic factor of the pathologic process of AD, PD, and cancer, understanding how intracellular signaling pathways respond to OS will have a significant implication in the therapy of these diseases. Here, we propose a model of minimal completeness of cell death signaling induced by OS as a mechanistic explanation of neuronal and cancer cell demise. This mechanism might provide the basis for therapeutic design strategies. Finally, we will attempt to associate PD, cancer, and OS. This paper critically analyzes the evidence that support the "oxidative stress model" in neurodegeneration and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.